Literature DB >> 31938210

Expression of Tim-3 in breast cancer tissue promotes tumor progression.

Shiqing Cheng1, Fuyan Han2, Yanqiu Xu1, Teng Qu1, Ying Ju1.   

Abstract

T-cell immunoglobulin mucin-3 (Tim-3) plays a pivotal role in immune regulation and tolerance induction as a negative regulatory molecule on innate versus adaptive immune cells, especially in antitumor immunity. However, the mechanism of Tim-3 expression on tumor cells and the mechanism that inhibits anti-tumor immunity are obscure. In this present study, we aimed to investigate the functions of Tim-3 in breast cancer and to explore its correlation to tumor prognosis. In a total of 42 clinical samples of invasive breast cancer, Tim-3 was semiquantitatively scored based on both distribution and intensity of immunohistochemistry staining and was found to correlate with clinicopathological parameters. Western blotting was used to detect the expression of Tim-3 in breast cancer cells. Furthermore, the effect of Tim-3 in breast cancer cells was evaluated after overexpression by ADV-Tim-3 and downregulation by Tim-3-siRNA. High immunoreactivity of Tim-3 was found to be significantly correlated with clinical stage, metastasis, KI67, and a lower 5-year survival rate. We supported this finding by confirming the presence of Tim-3 protein in the breast cell lines. Downregulation of Tim-3 significantly inhibited the proliferation, migration, and invasion of breast cancer cells while it promoted apoptosis. Overexpression of Tim-3 promoted the proliferation, migration, and invasion of breast cancer cells and inhibited apoptosis. Taken together, as a valuable marker of breast cancer prognosis, Tim-3 in breast cancer cells play an important role in the progression of breast cancer and may be an effective novel target in tumor prevention and treatment. IJCEP
Copyright © 2018.

Entities:  

Keywords:  Breast cancer; Ki67; SiRNA; Tim-3; downregulation; overexpression

Year:  2018        PMID: 31938210      PMCID: PMC6958123     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  36 in total

Review 1.  Proliferation marker Ki-67 in early breast cancer.

Authors:  Ander Urruticoechea; Ian E Smith; Mitch Dowsett
Journal:  J Clin Oncol       Date:  2005-10-01       Impact factor: 44.544

2.  The Tim-3 ligand galectin-9 negatively regulates CD8+ alloreactive T cell and prolongs survival of skin graft.

Authors:  Feng Wang; Wentao He; Hongmin Zhou; Jin Yuan; Ke Wu; Lijun Xu; Zhonghua Klaus Chen
Journal:  Cell Immunol       Date:  2008-03-18       Impact factor: 4.868

3.  Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients.

Authors:  Julien Fourcade; Zhaojun Sun; Mourad Benallaoua; Philippe Guillaume; Immanuel F Luescher; Cindy Sander; John M Kirkwood; Vijay Kuchroo; Hassane M Zarour
Journal:  J Exp Med       Date:  2010-09-06       Impact factor: 14.307

4.  Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy.

Authors:  Anne Vincent-Salomon; Alexandra Rousseau; Michel Jouve; Philippe Beuzeboc; Brigitte Sigal-Zafrani; Paul Fréneaux; Christophe Rosty; Claude Nos; François Campana; Jerzy Klijanienko; Abir Al Ghuzlan; Xavier Sastre-Garau
Journal:  Eur J Cancer       Date:  2004-07       Impact factor: 9.162

5.  T Cell Ig- and mucin-domain-containing molecule-3 (TIM-3) and TIM-1 molecules are differentially expressed on human Th1 and Th2 cells and in cerebrospinal fluid-derived mononuclear cells in multiple sclerosis.

Authors:  Mohsen Khademi; Zsolt Illés; Alexander W Gielen; Monica Marta; Naruhiko Takazawa; Claire Baecher-Allan; Lou Brundin; Jan Hannerz; Claes Martin; Robert A Harris; David A Hafler; Vijay K Kuchroo; Tomas Olsson; Fredrik Piehl; Erik Wallström
Journal:  J Immunol       Date:  2004-06-01       Impact factor: 5.422

6.  TIM-1 and TIM-3 enhancement of Th2 cytokine production by mast cells.

Authors:  Susumu Nakae; Motoyasu Iikura; Hajime Suto; Hisaya Akiba; Dale T Umetsu; Rosemarie H Dekruyff; Hirohisa Saito; Stephen J Galli
Journal:  Blood       Date:  2007-07-09       Impact factor: 22.113

7.  Ectopic expression of TIM-3 in lung cancers: a potential independent prognostic factor for patients with NSCLC.

Authors:  Xuewei Zhuang; Xiaoning Zhang; Xiyan Xia; Cuijuan Zhang; Xiaohong Liang; Lifen Gao; Xin Zhang; Chunhong Ma
Journal:  Am J Clin Pathol       Date:  2012-06       Impact factor: 2.493

Review 8.  TIM-3 is a potential prognostic marker for patients with solid tumors: A systematic review and meta-analysis.

Authors:  Yang Zhang; Pengcheng Cai; Tao Liang; Lin Wang; Lihua Hu
Journal:  Oncotarget       Date:  2017-05-09

9.  Tim-3 expression in cervical cancer promotes tumor metastasis.

Authors:  Yang Cao; Xiaoxi Zhou; Xiaoyuan Huang; Qinlu Li; Lili Gao; Lijun Jiang; Mei Huang; Jianfeng Zhou
Journal:  PLoS One       Date:  2013-01-15       Impact factor: 3.240

10.  Tim-3 expression defines regulatory T cells in human tumors.

Authors:  Jing Yan; Yi Zhang; Jing-Ping Zhang; Jing Liang; Lian Li; Limin Zheng
Journal:  PLoS One       Date:  2013-03-05       Impact factor: 3.240

View more
  3 in total

1.  Tim-3 promotes cell aggressiveness and paclitaxel resistance through NF-κB/STAT3 signalling pathway in breast cancer cells.

Authors:  Yizi Cong; Yuxin Cui; Shiguang Zhu; Jianqiao Cao; Haidong Zou; Tracey A Martin; Guangdong Qiao; Wenguo Jiang; Zhigang Yu
Journal:  Chin J Cancer Res       Date:  2020-10-31       Impact factor: 5.087

Review 2.  Therapeutic strategies for gastric cancer targeting immune cells: Future directions.

Authors:  Yan Zhao; Yuansong Bai; Meili Shen; Yapeng Li
Journal:  Front Immunol       Date:  2022-09-23       Impact factor: 8.786

Review 3.  Breast Cancer Tumor Microenvironment and Molecular Aberrations Hijack Tumoricidal Immunity.

Authors:  Huey-Jen Lin; Yingguang Liu; Denene Lofland; Jiayuh Lin
Journal:  Cancers (Basel)       Date:  2022-01-07       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.